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Abstract: The combination of amoxicillin and enrofloxacin is a well-known mixture of veterinary
drugs; it is used for the treatment of Gram-positive and Gram-negative bacteria. In the scientific
literature, there is no high-performance liquid chromatography (HPLC)-UV method for the
simultaneous determination of this combination. The objective of this work is to develop and
validate an HPLC method for the determination of this combination. In this regard, a new, simple and
efficient reversed-phase HPLC method for simultaneous qualitative and quantitative determination
of amoxicillin and enrofloxacin, in an injectable preparation with a mixture of inactive excipients, has
been developed and validated. The HPLC separation method was performed using a reversed-phase
(RP)-C18e (250 mm × 4.0 mm, 5 µm) column at room temperature, with a gradient mobile phase
of acetonitrile and phosphate buffer containing methanol at pH 5.0, a flow rate of 0.8 mL/min and
ultraviolet detection at 267 nm. This method was validated in accordance with the Food and Drug
Administration (FDA) and the International Conference on Harmonisation (ICH) guidelines and
showed excellent linearity, accuracy, precision, specificity, robustness, ruggedness, and system
suitability results within the acceptance criteria. A stability-indicating study was also carried
out and indicated that this method can also be used for purity and degradation evaluation of
these formulations.
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1. Introduction
The combination of the two antibacterial drugs amoxicillin and enrofloxacin is a well-known
mixture of veterinary drugs. In this drug, a synergistic effect has been demonstrated in vitro
between quinolones and β-lactams. This drug is indicated for the treatment of Gram-positive and
Gram-negative bacterial infections in the digestive tract, and in respiratory, intestinal, urinary, and
skin infections in cattle and dogs [1–3].
Amoxicillin (α-amino-hydroxy benzyl penicillin) is a broad-spectrum penicillin categorized under
the β-lactam class of antibiotics. It is a semi-synthetic antibiotic derived from a precursor molecule
called 6-aminopenicillanic acid [4]. Amoxicillin is bactericidal in action and interferes with cell wall
synthesis in bacteria by inhibiting cross-linking of peptidoglycan molecules, which is a cell wall
component in Gram-positive (major) and Gram-negative bacteria. It is effective against Staphylococcus
spp., Streptococcus pneumonia, Streptococcus spp., Enterococcus faecalis, Escherichia coli, Helicobacter pylori,
Sci. Pharm. 2017, 85, 6; doi:10.3390/scipharm85010006 www.mdpi.com/journal/scipharm
Sci. Pharm. 2017, 85, 6 2 of 8
Neisseria gonorrhoeae, Haemophilus influenza, Proteus mirabilis [4]. Enrofloxacin is a quinolone carboxylic
acid derivative with antimicrobial action. It is effective against a broad spectrum of Gram-negative
bacteria and is indicated for infections of the respiratory, gastrointestinal and urinary tracts in cattle,
pigs and poultry. Enrofloxacin is bactericidal through the inhibition of DNA-gyrase [5]. The structure
of amoxicillin trihydrate and enrofloxacin is shown in Figure 1.
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In the literature, there are many analytical methods for the individual determination of amoxicillin
trihydrate or enrofloxacin [4–14], but not for both of them simultaneously, by high-performance liquid
chromatography (HPLC)-UV. The objective of this study was therefore to develop and validate a simple
reverse-phase (RP)-HPLC method using a UV-PDA (photodiode array) detector to simultaneously
quantify amoxicillin and enrofloxacin. This method can be used for the assay of both active ingredients
in a single run. In addition, the method is stability-indicating, which provides a high degree of
analytical confidence, and it can specifically detect any degradation product that may be produced
during the study of stability or during its shelf life. This method was validated in accordance with
the requirements of Food and Drug Administration (FDA) and thr International Conference on
Harmonisation (ICH) guidelines [15–19].
2. Materials and Methods
2.1. Instrumentation
Chromatographic analysis was carried out using Dionex-Ultimate 3000 HPLC system equipped
with LPG-3400SD pump, WPS-3000SL autosampler, TCC-3000 column oven, and DAD-3000 UV- IS
diode array detector (Thermo Fisher Scientific, Waltham, MA, USA). Chromeleon Data system Software
(Version 6.80 DU10A Build 2826 (171948) Thermo Fisher Scientific) was used for data acquisition and
mathematical calculations.
2.2. Materials and Reagents
Amoxicillin and enrofloxacin active ingredients as referenc standards were purchased from USP
(Rockville, MD, USA). The injectable dosage f rm amoxicillin (as trihydrate) 100 mg per mL and
enrofloxacin 50 mg per L was formulated in house in R&D laboratory of the c mpany. The ethanol
and acetonitrile us d we e of HPLC grade and obtain d from Merck (Darmstat, Germany). Water for
HPLC analysis was obt ined by double distillation prepared by Aquatron equipment model A 4000D
(Bibby Sterilin Ltd., Stone, UK). Other reagents such as potassium dihydrogen phosphate, phosphoric
acid, hydrochloric acid, sod um hydroxide, and hydrogen peroxide were purchased from Merck
(Darmst t, Germany), Sigma Aldrich (Billerica, MA, USA) and J. T. Baker (Phillipsburg, NJ, USA).
2.3. Chromatographic Conditions
Buffer and acetonitrile were used in the preparation of the diluent (75% Buffer: 25% Acetonitrile)
and the mobile phase was run as gradient elution as follows: 95% buffer was run for one minute and
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then descended to 75% in one minute, and stayed there for six minutes, and then back to the initial
conditions (95% buffer) in five minutes, so 13 min is needed for complete elution of the two drugs and
degradation products. The HPLC system was equilibrated for five minutes with the initial conditions
(95% buffer) before injecting next sample.
The buffer used was prepared by mixing 75 mL methanol with 425 mL of 0.02 M KH2PO4, then
adjusted to pH 5.0 with 2 M H3PO4. The chromatographic conditions were run as follows: flow rate:
0.8 mL/min, wavelength: 267 nm, column temperature: 25 ◦C, injection volume: 20 µL.
2.4. Preparation of Standard Solution
A standard solution of amoxicillin (0.8 mg/mL) and enrofloxacin (0.4 mg/mL) was prepared by
dissolving an accurately weighed amount of amoxicillin trihydrate (114.8 mg which is equivalent to
100 mg amoxicillin) and 50 mg of enrofloxacin in 50 mL of 0.01 M HCl, then 10 mL of the resulting
solution was diluted to 25 mL by the diluent.
2.5. Preparation of Sample Solution
A sample solution from the suspension of amoxicillin and enrofloxacin was prepared with a
concentration equivalent to that in standard solution (0.8 mg/mL of amoxicillin and 0.4 mg/mL of
enrofloxacin) by transferring 2 mL of the suspension and about 200 mL of a mixture of 75% buffer and
25% acetonitrile into a 250-mL volumetric flask, the solution was sonicated with frequent shaking for
five minutes, and then the volume was completed to mark by the same mixture.
2.6. Method Validation
The method was validated according to ICH and FDA guidelines for specificity, linearity,
range, accuracy, precision, limit of detection (LOD)/limit of quantification (LOQ), ruggedness, and
robustness [15–19].
2.6.1. Specificity
Forced degradation was carried by exposing samples of the drug substance and drug product to
stress conditions of hydrolysis, oxidation, photo and thermal; the time and condition are illustrated in
Table 1. Stressed samples were analyzed occasionally; related peaks were checked for the retention
times, peaks interference, spectra purity and separation factors.
Table 1. Stress conditions applied for drug substance and drug product.
Stress Type Conditions Time
Acid hydrolysis 2 mg/mL in 0.1 N HCl at RT 4 h
Base hydrolysis 2 mg/mL in 0.1 N (up to 1 N), NaOH at 65 ◦C 7 days
Oxidative/solution 0.3% H2O2; at RT; protected from light 7 days
Thermal 70 ◦C 3 weeks
Photo-degradation UV light 3 days
RT: room temperature.
2.6.2. Linearity
To evaluate the linearity and range of the method, five different concentrations of amoxicillin (240,
320, 400, 480 and 560 µg/mL) and enrofloxacin (480, 640, 800, 960 and 1120 µg/mL) were prepared.
Three injections from each concentration were analyzed under the same conditions.
2.6.3. Accuracy and Precision
The accuracy and precision of the method were performed on three concentrations around the test
concentration (80%, 100% and 120%) by nine determinations (three replicates of each concentration).
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The percentage recovery and relative standard deviation (RSD) were calculated for each of the
replicate samples.
2.6.4. Limit of Detection and Limit of Quantification
LOD and LOQ of amoxicillin and enrofloxacin using this method was determined by analyzing
different dilute solutions of amoxicillin and enrofloxacin, and measuring signal to noise ratio. The limit
of detection is the concentration that gives a signal to noise ratio of ≥3, while the limit of quantification
in sample can be determined with acceptable precision and accuracy with a signal to noise ratio of ≥10.
2.6.5. Ruggedness and Robustness
The robustness of the method was determined by analyzing samples of the drug product and
standard solution using minor changes of the method conditions: mobile phase pH, detection
wavelength and flow rate. Ruggedness of the method was investigated by studying the effect of
different elapsed assay times and different lab analysts on the method performance. The applied
raggedness and robustness parameters are illustrated in Table 2.
Table 2. The applied ruggedness and robustness conditions for the method of determination of
amoxicillin and enrofloxacin.
Robustness/Ruggedness Parameter Conditions Checked
pH of the mobile phase 4.8, 5.0 & 5.2
Detection wavelength 265, 267 and 269 nm
Flow rate 0.7, 0.8 and 0.9 mL/min
Elapsed assay times
The same analyst analyzed the same trial in two
different days.
Same trial was analyzed at different times after preparing
the sample solution.
Different lab analysts Two lab analysts analyzed the same trial in the same day.
3. Results and Discussion
3.1. Method Development
Preliminary studies involved trying different stationary phases and testing several mobile phase
compositions for the effective separation of amoxicillin and enrofloxacin. Method development started
with testing three reversed-stationary phases (C4, C8, and C18 columns). Both analytes have retention
using all these stationary phases, but for good separation of the two analytes and the degradation
products as shown in Figure 2, stationary phase C18e (250 mm × 4.0 mm, 5 µm) was found to be
the best one for optimum separation, as shown in Figure 2. Regarding the mobile phase, a mixture
of acetonitrile and phosphate buffer containing methanol at pH 5.0 was tested both in isocratic and
gradient elution. Isocratic elution was not successful for the separation of the two analytes and the
degradation products even when using a high percentage of buffer. Therefore, the gradient elution
was used and optimized as reported in Section 2.3. Regarding the pH of the buffer, different pH values
were tested and we found that pH 5 was the best as it gave a better separation of the two analytes and
degradation products. Different flow rates of 1.2, 1.0, and 0.8 mL/min were tested, and we found that
0.8 mL/min was the best one. Room temperature was good for this separation and so it was used in
the whole separation. Ultraviolet detection at 267 nm was used as it was found to be the optimum
wavelength for the two analytes (amoxicillin and enrofloxacin) as it gave a high signal-to-noise ratio
and a high peak area for the two analytes. Using these conditions, good separation of the two analytes
and the degradation products was obtained (see Figure 2), and the diluent and placebo (mixture of
excipients) did not show a response in the region of the analytes.
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Figure 2. Chromatogram of well-separated peaks of the active ingredients (amoxicillin and enrofloxacin)
and the degradative materials. Concentration of amoxicillin and enrofloxacin is 0.8 and 0.4 mg/mL,
respectively. Degrade A and B are degradants from Amoxicillin.
linearity of the method was observed in the concentration range f 480 µg/mL to 1120 µg/mL
for amoxicillin and 240 µg/mL to 560 µg/mL for enrofloxacin, demonstrating its suitability fo analysi .
The goodness of fit (R2) was found to be 0.9999 and 1.0000 for amoxicillin and enrofloxacin, respectively,
indicating a lin ar relationship be ween th concentration of the analyt s a d the area under the peak.
3.3. Specificity and Stability-Indicating Study
Specificity is the ability of the analytical method to measure the active ingredient response in
the presence of other excipients, impurities and any potential degradants. Forced degradation was
carried out to evaluate the specificity and stability-indicating properties of the method, by exposing
samples of the drug substance and the drug product to conditions of hydrolysis, oxidation, photo and
thermal stresses.
Stress testing of the drug product was performed to induce forced degradation and to identify the
potential degradant products, the stability of the drug substance and also to validate the specificity
of the analytical procedures. The stability-indicating study was performed under the various stress
conditions mentioned in Section 2.6.1.
The acidic condition applied on the active drug substances for four hours induced the hydrolysis
of amoxicillin, causing an assay loss of about 26% and degradative materials (A) and (B) of about 17%
and 7.5%, respectively, while no degradation was observed for enrofloxacin. There was no evidence
of degradation of the drug substances when exposed to alkaline- and oxidative-type stresses. There
was no evidence of degradation of the drug product when exposed to thermal, oxidative and photo
stress conditions.
The results showed no interference between the chromatographic peaks of amoxicillin and
enrofloxacin and the excipients, impurities and degradation products under the various stress
conditions (Figure 2). The spectra of all the peaks were checked using PDA, showing perfect purity.
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3.4. Accuracy and Precision
The results of accuracy and precision testing showed that the method is accurate and precise within
the acceptable limits. The percentage recovery and RSD were calculated for both active ingredients,
amoxicillin and enrofloxacin, and all the results were within the limits. Acceptable accuracy was
within the range of 98.0% to 102.0% recovery, and the precision of the %RSD was not more than 2.0%,
as demonstrated in Table 3.
Table 3. Accuracy and precision results of amoxicillin (A) and enrofloxacin (B).
(A)
Amoxicillin Sample Peak Area Standard Peak Area Assay (%)
Sample No. inj # 1 inj # 2 Average inj # 1 inj # 2 Average
80%
1 43.30 43.30 43.30 43.30 43.30 43.30 100.00
2 42.70 42.70 42.70 98.61
3 43.10 43.10 43.10 99.54
100%
1 53.80 53.70 53.75 53.00 53.50 53.25 100.94
2 54.10 54.10 54.10 101.60
3 53.40 53.30 53.35 100.19
120%
1 63.90 63.90 63.90 63.60 63.00 63.30 100.95
2 63.80 63.80 63.80 100.79
3 64.00 64.10 64.05 101.18
Mean 100.42
SD 0.93
RSD 0.93
(B)
Enrofloxacin Sample Peak Area Standard Peak Area Assay (%)
Sample No. inj # 1 inj # 2 Average inj # 1 inj # 2 Average
80%
1 519.80 519.00 519.40 511.40 513.40 512.40 101.37
2 512.00 512.20 512.10 99.94
3 517.30 518.30 517.80 101.05
100%
1 667.50 668.30 667.90 655.50 656.10 655.80 101.85
2 674.30 673.60 673.95 102.77
3 664.30 666.90 665.60 101.49
120%
1 789.60 791.40 790.50 788.20 782.90 785.55 100.63
2 794.90 795.90 795.40 101.25
3 799.10 798.10 798.60 101.66
Mean 101.33
SD 0.79
RSD 0.78
Inj: injection; RSD: relative standard deviation.
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3.5. Ruggedness and Robustness
The ruggedness and robustness of the method were examined using the minor modifications
detailed in Table 2. The data obtained indicated that minor modifications of the experimental parameters
do not affect the assay and its ability to accurately and precisely detect/quantify the active ingredients.
3.6. Limit of Detection and Limit of Quantification
The limit of detection is the lowest amount of analyte in a sample that can be detected, but not
necessarily quantitated. It may be expressed as a concentration that gives a signal-to-noise ratio of
approximately 3:1. The limit of quantification is the lowest amount of analyte in a sample that can
be quantitatively determined with suitable accuracy and precision, with a signal-to-noise ratio of
approximately 10:1. The method showed LOQs of 6.9 and 0.24 mg/L for amoxicillin and enrofloxacin,
respectively; and LODs of 2.0 and 0.074 mg/L for amoxicillin and enrofloxacin, respectively.
3.7. System Suitability
System suitability parameters were measured to verify the system, method, and column
performance by evaluation of the column efficiency and the ability to separate peaks. Column efficiency
is usually represented by the number of theoretical plates for each peak. According to FDA regulations,
the number of theoretical plates for each peak must not be less than 1000 to have good separation [15].
In addition to the theoretical plates, the tailing factor is another parameter of system suitability which
reflects the symmetry of the peak. The peak should be symmetrical with minimal peak broadening or
fronting, which should be less than 2.0 according to FDA regulations [15]. The resolution between the
adjacent peaks is another parameter of system suitability where good resolution is required to obtain
good separation of the adjacent peaks. According to the FDA regulations, resolution should be not less
than 1.5 [15].
The current method shows that all the values for the system suitability parameters are within
the acceptable limits. The column efficiencies were 9671 and 3372 theoretical plates for amoxicillin
and enrofloxacin, respectively. The tailing factors were 1.11 and 0.93 for amoxicillin and enrofloxacin,
respectively. The resolution between amoxicillin and enrofloxacin was 3.8.
4. Conclusions
A simple, accurate, and precise stability-indicating HPLC method was developed and validated for
routine qualitative and quantitative analysis of amoxicillin and enrofloxacin in an injectable formulation.
The method is stability-indicating, and therefore qualified and reliable for demonstrating
and detecting any expected change or degradation in the drug product during stability studies.
The method is robust and rugged enough to reproduce accurate and precise results under different
method conditions.
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